Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coeptis Therapeutics Holdings (COEP) Depreciation & Amortization (CF) (2022 - 2025)

Coeptis Therapeutics Holdings (COEP) has 4 years of Depreciation & Amortization (CF) data on record, last reported at $295303.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 18.02% year-over-year to $295303.0; the TTM value through Sep 2025 reached $1.1 million, up 13.51%, while the annual FY2024 figure was $1.0 million, 0.04% changed from the prior year.
  • Depreciation & Amortization (CF) reached $295303.0 in Q3 2025 per COEP's latest filing, roughly flat from $295303.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $295303.0 in Q1 2025 and bottomed at $250211.0 in Q1 2024.
  • Average Depreciation & Amortization (CF) over 4 years is $259291.7, with a median of $250310.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): decreased 0.04% in 2024, then grew 18.02% in 2025.
  • A 4-year view of Depreciation & Amortization (CF) shows it stood at $250346.0 in 2022, then fell by 0.01% to $250310.0 in 2023, then decreased by 0.04% to $250212.0 in 2024, then increased by 18.02% to $295303.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $295303.0 in Q3 2025, $295303.0 in Q2 2025, and $295303.0 in Q1 2025.